Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Insulin; related peptides
Reexamination Certificate
2007-06-01
2010-11-09
Hill, Kevin K. (Department: 1633)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Insulin; related peptides
C424S093100, C424S093210, C435S069400, C435S069700, C435S071100, C435S320100, C514S002600, C514S04400A, C530S324000, C530S399000, C536S023100, C536S023510
Reexamination Certificate
active
07829664
ABSTRACT:
An isolated chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1 is provided. Also provided is an isolated modified chimeric GLP-1 nucleic acid sequence encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1. Recombinant expression vectors comprising the chimeric GLP-1 nucleic acid sequences, which produce GLP-1 constitutively are provided, as are human cells transfected with such an expression vector in combination with an expression vector comprising a proinsulin nucleic acid sequence and an expression vector comprising a furin and a glucose-regulatable TGF-alpha promoter. Methods of producing human GLP-1 constitutively are provided as are method of producing GLP-1 and insulin or in a glucose-dependent manner using such transfected cells. Methods of treating a subject having Type II diabetes and methods of treating a subject prone to hyperglycemia or suffering from hyperglycemia are provided in which transfected cells produce human GLP-1 and insulin in a glucose-dependent manner. Also provided are methods of reducing weight in a subject by implanting into the subject transfected cells which produce human GLP-1 and insulin in a glucose-dependent manner.
REFERENCES:
patent: WO0136643 (2001-05-01), None
patent: WO03014318 (2003-02-01), None
patent: WO03030946 (2003-04-01), None
Sures et al, Science 208(4439):57-59, 1980.
International Search Report and Written Opinion of the International Application No. PCT/US2008/065015.
M. Kumar, Y. Hunag, Y. Glinka, GJ Prud'Homme, Q. Wang, Gene therapy of diabetes Using a novel GLP-1/1gG1-Fc fusion construct normalizes glucose levels in db/db mice, Gene Therapy (2007) 14, 162-172 XP-002499114.
GB Parsons, DW Souza, H. Wu, D. Yu, SG Wadsworth, RJ Gregory, D. Armentano, Ectopic expression of glucagon-like peptide 1 gene therapy of type II diabetes, Gene Therapy (2007) 14, 38-48 XP-002499115.
Monaco Kelli-Ann
O'Neill Margaret M.
Tatake Revati J.
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Hill Kevin K.
Lebel Edouard G.
Morris Michael P.
LandOfFree
Modified nucleotide sequence encoding glucagon-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified nucleotide sequence encoding glucagon-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified nucleotide sequence encoding glucagon-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223285